Scientific Reports (Oct 2022)

Gender differences in fasting and postprandial metabolic traits predictive of subclinical atherosclerosis in an asymptomatic Chinese population

  • Xinpeng Loh,
  • Lijuan Sun,
  • John Carson Allen,
  • Hui Jen Goh,
  • Siew Ching Kong,
  • Weiting Huang,
  • Cherlyn Ding,
  • Nabil Bosco,
  • Leonie Egli,
  • Lucas Actis-Goretta,
  • Faidon Magkos,
  • Fabrizio Arigoni,
  • Khung Keong Yeo,
  • Melvin Khee-Shing Leow

DOI
https://doi.org/10.1038/s41598-022-20714-6
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 14

Abstract

Read online

Abstract The prediction utility of Framingham Risk Score in populations with low conventional cardiovascular risk burden is limited, particularly among women. Gender-specific markers to predict cardiovascular risk in overtly healthy people are lacking. In this study we hypothesize that postprandial responses triggered by a high-calorie meal test differ by gender in their ability to triage asymptomatic subjects into those with and without subclinical atherosclerosis. A total of 101 healthy Chinese subjects (46 females, 55 males) at low risk of coronary heart disease completed the study. Subjects underwent cardiovascular imaging and postprandial blood phenotyping after consuming a standardized macronutrient meal. Prediction models were developed using logistic regression and subsequently subjected to cross-validation to obtain a de-optimized receiver operating characteristic (ROC) curve. Distinctive gender differences in postprandial trajectories of glucose, lipids and inflammatory markers were observed. We used gender-specific association with different combinations of postprandial predictors to develop 2 models for predicting risk of subclinical atherosclerosis in males (ROC AUC = 0.7867, 95% CI 0.6567, 0.9166) and females (ROC AUC = 0.9161, 95% CI 0.8340, 0.9982) respectively. We report novel postprandial models for predicting subclinical atherosclerosis in apparently healthy Asian subjects using a gender-specific approach, complementing the conventional Framingham Risk Score. Clinical Trial Registration: The trial was registered at clinicaltrials.gov as NCT03531879.